In Brief: Glaxo Wellcome
This article was originally published in The Tan Sheet
Executive Summary
Glaxo Wellcome: Low-dose Zantac (ranitidine hydrochloride) in 75 mg tablets is recommended for OTC regulatory approval in Austria, Belgium, France, Germany, Italy and Luxembourg under the EU's new centralized mutual recognition procedure. The Netherlands, which approved the product in December 1995, served as the reference member state. Zantac 75 was launched in the U.K. in January 1995 and the U.S. in April 1996. Warner-Lambert will handle marketing of the product in most countries under the two companies' joint venture agreement ("The Tan Sheet" July 8, In Brief)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning